Fredrik Schjesvold
Academic History
Fredrik Schjesvold, MD, PhD, is the Founder and Head of the Oslo Myeloma Center at Oslo University Hospital, Oslo, Norway. He also serves as Head of the Norwegian Myeloma Association and is President of the Nordic Myeloma Study Group, where he leads the clinical trial task force. Dr Schjesvold earned his medical degree from the University of Oslo and completed his specialist training in hematology at the Department of Hematology at Oslo University Hospital. He previously held leadership positions as Head of the Hematology Units at both Diakonhjemmet Hospital and Bærum Hospital in Norway. Dr Schjesvold is actively involved in shaping clinical practice and trial design at both the national and international levels. He is the main author of the Norwegian Myeloma Guidelines and serves on the board of the European Myeloma Network.
Speaking on clinical innovation in multiple myeloma
Dr Schjesvold specializes in the clinical management and translational research of multiple myeloma, with a particular focus on early-phase clinical trials involving immunotherapies, as well as strategies for therapeutic sequencing and combination treatments. His work spans both the relapsed/refractory and newly diagnosed settings, where he investigates next-generation monoclonal antibodies, bispecific T-cell engagers, and other novel therapeutic modalities.
